Sanofi Pasteur, Beijing, China
BMC Med Res Methodol. 2013 Mar 1;13:29. doi: 10.1186/1471-2288-13-29.
Immunological correlates of protection are biological markers such as disease-specific antibodies which correlate with protection against disease and which are measurable with immunological assays. It is common in vaccine research and in setting immunization policy to rely on threshold values for the correlate where the accepted threshold differentiates between individuals who are considered to be protected against disease and those who are susceptible. Examples where thresholds are used include development of a new generation 13-valent pneumococcal conjugate vaccine which was required in clinical trials to meet accepted thresholds for the older 7-valent vaccine, and public health decision making on vaccination policy based on long-term maintenance of protective thresholds for Hepatitis A, rubella, measles, Japanese encephalitis and others. Despite widespread use of such thresholds in vaccine policy and research, few statistical approaches have been formally developed which specifically incorporate a threshold parameter in order to estimate the value of the protective threshold from data.
We propose a 3-parameter statistical model called the a:b model which incorporates parameters for a threshold and constant but different infection probabilities below and above the threshold estimated using profile likelihood or least squares methods. Evaluation of the estimated threshold can be performed by a significance test for the existence of a threshold using a modified likelihood ratio test which follows a chi-squared distribution with 3 degrees of freedom, and confidence intervals for the threshold can be obtained by bootstrapping. The model also permits assessment of relative risk of infection in patients achieving the threshold or not. Goodness-of-fit of the a:b model may be assessed using the Hosmer-Lemeshow approach. The model is applied to 15 datasets from published clinical trials on pertussis, respiratory syncytial virus and varicella.
Highly significant thresholds with p-values less than 0.01 were found for 13 of the 15 datasets. Considerable variability was seen in the widths of confidence intervals. Relative risks indicated around 70% or better protection in 11 datasets and relevance of the estimated threshold to imply strong protection. Goodness-of-fit was generally acceptable.
The a:b model offers a formal statistical method of estimation of thresholds differentiating susceptible from protected individuals which has previously depended on putative statements based on visual inspection of data.
免疫保护相关物是一些生物学标志物,如针对特定疾病的抗体,它们与疾病的保护相关,并且可以通过免疫学检测来测量。在疫苗研究和免疫政策制定中,通常依赖于相关物的阈值,该阈值区分了被认为可以预防疾病的个体和易感染的个体。使用阈值的例子包括开发新一代 13 价肺炎球菌结合疫苗,该疫苗在临床试验中需要满足对旧的 7 价疫苗的接受阈值,以及基于甲型肝炎、风疹、麻疹、乙型脑炎和其他疾病的保护性阈值的长期维持的公共卫生决策。尽管在疫苗政策和研究中广泛使用了这种阈值,但很少有正式开发的统计方法特别纳入阈值参数,以便根据数据估计保护阈值的值。
我们提出了一个称为 a:b 模型的三参数统计模型,该模型纳入了使用轮廓似然或最小二乘法估计的阈值和常数参数,但在阈值以下和以上的感染概率不同。通过使用修正的似然比检验来评估阈值的存在,可以对估计的阈值进行显著性检验,该检验遵循自由度为 3 的卡方分布,并且可以通过自举法获得阈值的置信区间。该模型还允许评估达到或未达到阈值的患者的感染相对风险。可以使用 Hosmer-Lemeshow 方法评估 a:b 模型的拟合优度。该模型应用于 15 个已发表的关于百日咳、呼吸道合胞病毒和水痘的临床试验数据集。
在 15 个数据集中的 13 个数据集上发现了具有小于 0.01 的 p 值的高度显著阈值。置信区间的宽度存在相当大的差异。在 11 个数据集中,相对风险表明有 70%或更好的保护,并且估计的阈值与强烈保护相关。拟合优度通常可以接受。
a:b 模型提供了一种正式的统计方法来估计区分易感个体和保护个体的阈值,这以前依赖于基于数据直观观察的假设陈述。